million people affected worldwide
Psychedelic research currently is in Preclinical
Microdosing is the practice of regularly using low doses of psychedelic drugs. This relatively recent phenomenon was made popular through the anecdotal reports of young professionals from all walks of life, taking sub-hallucinogenic doses of psychedelics for a variety of reasons. Given that people tend to take higher doses of psychedelics for reasons relating to self-exploration, recreation or spiritual purposes, people’s reasons differ for taking psychedelics in such small quantities. Based on anecdotal reports, people’s reasons for microdosing include; improving their mental wellbeing, enhancing their emotional state or even boosting their focus and creativity as they go about their daily lives (Ghosh, 2018). The types of psychedelics used when mircodosing differ from person to person however, minuscule doses of psilocybin-containing mushrooms and LSD tend to be the most popular. Despite a large body of research indicating the positive outcomes of microdosing, many of the studies use a self-reported measure such as surveys and questionnaires and as a result, cannot be used as reliable clinical evidence. Few, if any, scientific studies exist that have specifically explored the pharmacological effects of microdosing and the actual perceived benefits people are reporting. Moreover, no double-blind randomized placebo-controlled trial exists, the ‘gold-standard for testing drug safety and efficacy, exploring the effects of microdosing. Such studies are needed in order to assess both the physiological and cognitive parameters through which microdosing exerts its effects as well as, illuminate any potential negative effects of this practice. Nonetheless, given the wide range of benefits, people are reporting, this particular area of psychedelic science isn’t going unnoticed.
Numerous large-scale survey studies exist exploring why people microdose and the subsequent effects they experience after regularly consuming low doses of psychedelics. One study involving 909 participants found that the most commonly microdosed drugs were LSD (13μg) and psilocybin (0.3g), on a one-day on and two-day off schedule. The same study reported that people who microdose were less likely to report a history of substance use disorders or anxiety disorders. A similar study explored the reported effects of microdosing in 404 individuals who had been diagnosed with a mental or physiological disorder. The researchers found that by microdosing had a significant therapeutic impact on the symptoms of ADHD/ADD when compared to conventional treatments. Hutten and colleagues (2019) found in their survey of 116 microdosers, that one-fifth of this population reported unwanted side effects be them psychological or physical. The same study reported that the majority of participants ceased microdosing due to it being ineffective. In nearly all published studies which explore the effects of microdosing, individual authors share the same conclusion; randomized controlled trials are needed in this area of research.
Kim Kuypers and colleagues (2019) were the first to take the steps toward building a framework for a more scientifically rigorous study of microdosing. In their study, they suggest the term microdosing consists of three components:
- The use of a low dose below the perceptual threshold that does not impair ‘normal’ functioning of an individual.
- A procedure that includes multiple dosing sessions.
- The intention to improve well-being and enhance cognitive and/or emotional processes.
Future clinical trials exploring the effects of microdosing, should include several different validated psychological instruments and preferably cover the concepts mentioned in the Research Domain Criteria. Additionally, during such trials physiological effects should be continuously monitored as well as the long-term effects of multiple low-dose administrations of psychedelics (Kuypers, et al., 2019). Recently, Murphy and colleagues (2021) published their study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers. This study plans to administer 14 doses of placebo or 10μg of LSD every third day over a 6-week treatment protocol. Measures will include personality, creativity, mood, cognition, electroencephalogram (EEG) to determine brain plasticity as well as resting-state fMRI imaging. A recent study carried out by a research team at Imperial College London is perhaps the first of its kind to investigate the effects of microdosing in slinge-blind placebo-controlled participants. A total of 191 participants received online instructions on how to incorporate placebo control into their microdosing routine without clinical supervision. In both the placebo and study groups, psychological outcomes improved significantly by the end of the study, with no significant difference between groups. Such findings led the researchers to conclude that the anecdotal benefits of microdosing can be explained by the placebo effect, an improvement in symptom despite using a nonactive treatment (Szigeti, et al., 2021). The findings from this study also received attention in the media, with The Guardian, Medical News and News Atlas reporting on the study. Although the study outcome doesn’t point to the benefits of microdosing, such reports in the media are helping to ease psychedelics back into the public discourse with accompanying positive connotations.
A number of companies are looking toward enhancing the availability of microdosing. Vancouver based, Better Plant Sciences offer high-efficacy plant-based products for optimum health and wellness. Their subsidiary, Flourish Mushroom Labs, has a portfolio of over 100 psilocybin formulas. In 2020, Flourish field provisional patents in the US for their psilocybin/psilocin microdose treatments to encourage weight loss. Gilgamesh Pharmaceuticals pipeline includes a non-hallucinogenic serotonin receptor agonist administered as a microdose for ADHD and depression and anxiety disorders. One of the many endeavours of MindMed, they are currently exploring the effects of microdosed LSD on a cognitive performance, sleep quality, mood, neuroplasticity markers, emotion regulation, quality of life, and immune system response, in collaboration with Dr. Kim Kuypers of Maastricht University. MindMed’s microdosing division is also undertaking a Phase-IIa trial evaluating the effects of microdosed LSD in adults with ADHD.
Notwithstanding, it is clear that if we truly want to prove or disprove the many self-reported benefits of microdosing, rigorous clinical trials are needed. One of the factors that is helping to advance psychedelics through the clinical trial process is the fact that they are being used to treat notoriously difficult to treat mental disorders. The fact that many anecdotal reports of microdosing come from healthy individuals seeking to better their mental wellbeing may have initially limited clinical trials taking place.. However, as psychedelic science progresses, research will emerge into this particular are of psychedelic science as it also holds promise for helping people with mental disorders.
- Ghosh, I. (2018). How and why people ‘microdose’ tiny hits of psychedelic drugs. CBC News. Retrieved from https://www.cbc.ca/news/health/microdosing-pschedelics-study-1.4771647
- Hutten, N., Mason, N., Dolder, P., & Kuypers, K. (2019). Motives and Side-Effects of Microdosing With Psychedelics Among Users. International Journal of Neuropsychopharamcology. Retrieved from https://blossomanalysis.com/papers/motives-and-side-effects-of-microdosing-with-psychedelics-among-users/
- Kuypers, K., Ng, L., Erritzoe, D., Knudsen, G., Nichols, C., Nichols, D., . . . Nutt, D. (2019). Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. Jounral of Psychopharmacology. Retrieved from https://blossomanalysis.com/papers/microdosing-psychedelics-more-questions-than-answers-an-overview-and-suggestions-for-future-research/
- Murphy, R., Sumner, R., Evans, W., Menkes, D., Lambrecht, I., Ponton, R., . . . Muthukumaraswamy, S. (2021). MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers. Biomedical Central. Retrieved from https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05243-3
- Szigeti, B., Kartner, L., Blemings, A., Rosas, F., Feilding, A., Nutt, D., . . . Erritzoe, D. (2021). Self-blinding citizen science to explore psychedelic microdosing. eLife. Retrieved from https://blossomanalysis.com/papers/self-blinding-citizen-science-to-explore-psychedelic-microdosing/
These are the institutes, from companies to universities, who are working on Microdosing.
Woke Pharmaceuticals is an Australian biotech company developing novel psychedelic compounds.
MindBio Therapeutics is conducting clinical research exploring the effects of microdosing psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opioid addiction.
These are some of the best-known people, from researchers to entrepreneurs, working on Microdosing.
Vince Polito is a Senior Research Fellow in the School of Psychological Sciences, and a member of the Biomolecular Discovery Research Centre at Macquarie University.
Linked Research Papers & Trials
Pro & Business members will be able to see all linked papers and trials directly on this topic page.
This information is still available for you by selecting Microdosing on the Papers and Trials pages respectively.
See the information directly on this page with a paid membership.